Yoshinobu Nagasawa
University of Yamanashi
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yoshinobu Nagasawa.
Journal of Hypertension | 2016
Kiyoshi Sakuma; Tatsuo Chiba; Takenori Morishita; Mari Yamanaka; Megumi Aimoto; Yoshinobu Nagasawa; Koji Shirai; Akira Takahara
Objective: The arterial stiffness is known to be a good predictor of cardiovascular events in hypertensive patients. Cardio-ankle vascular index (CAVI) has been developed for measurement of vascular stiffness from the aorta to tibial artery, which is clinically utilized for assessing the progress of arteriosclerosis. Our recent study has demonstrated that the CAVI is decreased by a vasodilator affecting conduit and muscular arteries. In this study, we compared acute effects of various types of vasodilators on the CAVI in anesthetized rabbits. Design and Method: New Zealand White rabbits were anesthetized with halothane. For measurements of the heart-ankle pulse wave velocity (haPWV) and CAVI, the signals of electrocardiogram, phonocardiogram and blood pressure were fed to the VaSera system to be automatically calculated from the following well-established basic equation: CAVI = (2&rgr;/&Dgr;P) × ln(Ps/Pd) × haPWV2, where Ps is systolic blood pressure, Pd is diastolic blood pressure, haPWV is heart-ankle pulse wave velocity, &Dgr;P is Ps–Pd, &rgr; is blood density. Results: Intravenous administration of nitroglycerin or acetylcholine decreased the CAVI accompanied with hypotensive action and reduction of the haPWV. Intravenous administration of nifedipine, nicardipine or cilnidipine unaffected the CAVI, whereas each drug decreased the blood pressure and haPWV. On the other hand, intravenous administration of nicorandil increased the CAVI but decreased the blood pressure and haPWV. Conclusions: Acute effects on the CAVI were different among the vasodilators examined. Pharmacological properties like nitroglycerin and acetylcholine will be beneficial for the prevention of arteriosclerotic diseases of the large artery.
Japanese Circulation Journal-english Edition | 2001
Yoshinobu Nagasawa; Sadayoshi Komori; Mitsuko Sato; Yoshiko Tsuboi; Ken Umetani; Yuichiro Watanabe; Kohji Tamura
Journal of Pharmacological Sciences | 2003
Jianguang Chen; Yoshinobu Nagasawa; Bing-Mei Zhu; Masami Ohmori; Ken-ichi Harada; Akio Fujimura; Keitaro Hashimoto
Japanese Circulation Journal-english Edition | 2001
Yoshinobu Nagasawa; Sadayoshi Komori; Mitsuko Sato; Yoshiko Tsuboi; Ken Umetani; Yuichiro Watanabe; Kohji Tamura
Japanese Journal of Pharmacology | 2002
Shigeki Miyamoto; Bing-Mei Zhu; Kazunori Kamiya; Yoshinobu Nagasawa; Keitaro Hashimoto
European Journal of Pharmacology | 2005
Yoshinobu Nagasawa; Bing-Mei Zhu; Jianguang Chen; Kazunori Kamiya; Shigeki Miyamoto; Keitaro Hashimoto
Journal of Pharmacological Sciences | 2003
Yoshiki Saegusa; Atsushi Sugiyama; Akira Takahara; Yoshinobu Nagasawa; Keitaro Hashimoto
Journal of Pharmacological Sciences | 2007
Jianguang Chen; Hua Shen; Yoshinobu Nagasawa; Kazuhiro Mitsui; Kunio Tsurugi; Keitaro Hashimoto
Journal of Pharmacological Sciences | 2006
Nobuo Homma; Shah Amran; Yoshinobu Nagasawa; Keitaro Hashimoto
Journal of Pharmacological Sciences | 2003
Bing-Mei Zhu; Shigeki Miyamoto; Yoshinobu Nagasawa; Teruaki Wajima; Keitaro Hashimoto